Fundraising net proceeds go to COVID-19 Solidarity Response Fund for WHO

Gene and Cell Therapies – A Major Investment Focus in 2020

2020 will soon be a record year for biotechnology. In the first half of 2020, the biotechnology industry obtained $16.55 billion in investment. Cell and gene therapy biotechs secured the lion share of investment by raising $10.7 billion. Notably, the amount raised by cell and gene therapy biotechs increased by 120% during the same time period of 2019.1 Thus far, the increase in this year’s investing appears to be driven by venture capitalists (VCs) as they contributed approximately 30% of the total investment.

Classical gene therapy involves the use of a recombinant form of a virus to deliver genes or gene-modifying nucleic acids to target tissues in order to replace defective genes causing disease. Genetically modified cells are made from patient-derived stem or allogeneic cells, and a viral vector that mediates the integration of genes that will enable the cells, when implanted back into the patient, to propagate and replace the diseased cells and enable normal tissue function. Both approaches are widely accepted as having the potential to change the way we treat congenital, degenerative, and chronic diseases.

Since the first gene therapy trials in the early 1990s, the road has been long and troubled with authorizing this approach for clinical use. However, recent successes have shown promises with the approvals of Glybera and Imlygic, viral vectors designed for gene therapy of lipoprotein lipase deficiency and melanoma, respectively.  In addition, Kymriah and Yescarta, two forms of T-cells that are removed from a patient and genetically engineered to make specific cell surface receptors and then transferred back into patients, have been approved for B-cell acute lymphoblastic leukemia and non-Hodgkin’s lymphoma, respectively. Thus, gene and cell therapies have finally arrived and appear they will only become better through the integration of important enabling technologies. Moreover, it appears VCs have identified and are pursuing the companies that are creating these enhancement technologies.

Gene and Cell Companies with the Highest Investments from Venture Capitalists

Sana Biotechnology

Sana Biotechnology appears to have cracked the code for the development of “universal donor cells”. Although the concept of cell replacement therapy is outstanding, the process of generating pluripotent stem cells is too long and expensive and the scientific process is highly variable with regards to the quality of the cells generated. In addition, there has yet to be a reliable scientific approach to make replacement donor cells non-immunogenic. Sana Biotechnology announced in 2019 that it had the ability to not only genetically reprogram cells, but make them scalable, cost-efficient and non-immunogenic. 3

Sana Biotechnology reported in June 2020 that its initial series A funding raised over  $700 million from multiple investors including VCs, including ” ARCH Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, F-Prime Capital, Alaska Permanent Fund, the Public Sector Pension Investment Board, Bezos Expeditions, GV, Omega Funds, Altitude Life Science Ventures.” 4 With this initial funding, Sana Biotechnology hopes to continue developing gene delivery, immunology, stem cell biology, and gene modification and control.4  The amount that Sana Biotechnology raised is almost as much “as much as the next five largest private rounds raised by Orca Bio, Elevate Bio, Legend, Freeline Therapeutics, and Poseida.”5 Comparatively, the largest amount invested in a biotechnology company who is not researching cell and gene therapy is $390 million, in Series D funding raised by Grail who are focusing on blood tests for cancer diagnosis.6

Lyell Immunopharma

Lyell Immunopharma is a cell therapy company that is focused on “advancing the science of T cell differentiation, functionality, and target specificity in order to develop curative treatments for solid tumors. These technologies can be used as a platform for multiple new cell therapies that can be applied across a broad range of cancers”7. In total, the company raised $493 million in Series C funding with an undisclosed amount of investors. Pharmaceutical firm GlaxoSmithKline, which has a capital venture fund under its name, Action Potential Venture Capital, reported that they invested £258 million (approximately $320 million) on equity investments primarily into Lyell Immunopharma.8 Lyell Immunopharma raised more money in Series C funding than any other biotechnology startup in the series.9 The second largest was XtalPi, an AI drug startup, with $318.8 million. This is roughly $175 million less than Lyell Immunopharma. The amount that SoftBank, the lead investor for XtalPi, invested in the company is undisclosed at this time. However, the data signifies that it was less than $318 million as XtalPi had seven investors participate in Series C funding, four of them being the main contributors.9

Orca Bio

Orca Bio is a biotechnology company that focuses on developing high precision allogeneic cell therapies. These cell therapies are “designed to safely and effectively replace a patient’s blood and immune system with a healthy one. The manufacturing platform sorts donor blood with single-cell precision and a high level of purity and speed, enabling the creation of proprietary, optimal therapeutic mixtures of immune and stem cells that have the potential to transform allogeneic cell therapy.”10 The company raised in Series D funding $192 million, in addition to the already roughly $200 million that was raised in previous years. Their lead investor was LightSpeed Venture Partners, along with one other undisclosed investor. Other investors in this series included “8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust, and IMRF.”10

Interestingly, on September 02, 2020, Orca Bio and Lyell Immunopharma announced a research partnership to “jointly identify next-generation T-cell therapies that will combine the high-precision purification T cell technologies from Orca Bio with the scientific expertise in T cell biology from Lyell to generate potentially synergistic therapeutic solutions for solid tumors.”11 This indicates that there will be more than $600 million in VC funding between the two biotechnology startups from their respective latest funding rounds.

Between all the investments made in between Series A to D, Sana Biotechnology and Lyell Immunopharma rank number two and number three, respectively, in the largest amount of money raised during this past year.12 Just between the two companies, they raised $1.193 billion out of the $10.7 billion that was invested in cell and gene therapy. This accounts for roughly 40% of all the money invested by VCs in cell and gene therapy.

The funding of biotechnology startups who are studying gene and cell therapy is not surprising. The field made some significant advancements in 2019 and is forecasted to grow over 24% CAGR (Compound Annual Growth Rate) over 2018-202413. The revenue in this field is expected to increase over 30.9% between 2019-2025.13 Hence, cell and gene therapy are now becoming a clinical reality and the aggressive investment is a strong signal that this form of therapy will impact the clinic and business in the near future.

Conclusion

Cell and gene therapy had a successful 2020. The amount of funding and the multitude of investors funding each company shows that this area of research is what the world, as well as the investors, are looking for. The funding will help these companies reach the world market at a faster pace, thus advancing science and humanity.

Bioinsider is hosting an informal Friday Roundtable Event on Friday, Jan. 29 covering “How COVID-19 is Driving Venture Investments in Healthcare Innovation” from 11:45 AM EST to 1:00 PM. Sign up and join this discussion here.


Author: Nicole Ludwiak 

 

 

References

  1. Alliance for Regenerative Medicine. (2020, August 6). New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19. GlobeNewswire News Room. http://www.globenewswire.com/news-release/2020/08/06/2074281/0/en/New-Report-Regenerative-Medicine-Advanced-Therapies-Sector-Thriving-Despite-COVID-19.html
  2. Constance, J. (2020, September 3). Small Biopharma Companies Emerging in Gene and Cell Therapy. BioSpace. https://www.biospace.com/article/small-biopharma-companies-emerging-in-gene-and-cell-therapy-/
  3. January 04, 2019 Sana Biotechnology Press Release. https://sana.com/sana-biotechnology-launches-focusing-on-engineering-cells-to-create-a-new-class-of-medicines-4/
  4. (2020, June 23). Announces Completion of Initial Financing. Sana Biotechnology. https://sana.com/sana-biotechnology-announces-completion-of-initial-financing/
  5. Idrus, A. A. (2020, August 6). In the face of COVID-19, cell and gene therapy space shows ‘remarkable resilience:’ report. FierceBiotech. https://www.fiercebiotech.com/biotech/face-covid-19-cell-and-gene-therapy-space-shows-remarkable-resilience-report
  6. Glasner, J. (2020, July 22). Life Science Funding Spikes In…Crunchbase News. https://news.crunchbase.com/news/life-science-funding-spikes-in-2020/
  7. Bio, O. (2020, September 2). Orca Bio and Lyell Immunopharma Announce Research Partnership. GlobeNewswire News Room. https://www.globenewswire.com/news-release/2020/09/02/2087609/0/en/Orca-Bio-and-Lyell-Immunopharma-Announce-Research-Partnership.html
  8. Lavine, R. (2020, March 30). GSK displays Lyell Immunopharma investment. Global Corporate Venturing. https://globalcorporateventuring.com/gsk-lyell-immunopharma-investment/
  9. Advanced Search | Funding Rounds. (, 2020). Crunchbase. https://www.crunchbase.com/discover/funding_rounds/4a2ad41015d5f0a14db0b701ed690baf
  10. Bio, O. (2020a, June 17). Orca Bio Emerges With Nearly $300 Million to Transform Allogeneic Cell Therapy. GlobeNewswire News Room. https://www.globenewswire.com/news-release/2020/06/17/2049369/0/en/Orca-Bio-Emerges-With-Nearly-300-Million-to-Transform-Allogeneic-Cell-Therapy.html
  11. Orca Bio and Lyell Immunopharma Announce Research Partnership. (, 2020). Orca Bio. https://orcabio.com/2020-09-02/
  12. Advanced Search | Funding Rounds- Series A to Series D. (2020). Crunchbase. https://www.crunchbase.com/discover/funding_rounds/ad86f5e2a56b8b304ad48489fe3e1126
  13. Cell & Gene Therapy Market – Global Outlook and Forecast 2020-2025. (, 2020). Report Linker. https://www.reportlinker.com/p05827567/Cell-and-Gene-Therapy-Market-Global-Outlook-and-Forecast.html?utm_source=PRN
Share on linkedin
LinkedIn
Share on twitter
Twitter
Share on facebook
Facebook
Share on xing
XING
Share on email
Email

You may also be interested in...

James E. Crowe, Jr., MD,

Director, Vanderbilt Vaccine Center; Professor, Pediatrics and Pathology, Microbiology and Immunology, Ann Scott Carell Chair; Founder, IDBiologics

Dr. Crowe’s laboratory has a broad portfolio of work in the area of viral immunology and antibody sciences, with the goal to discover mechanisms of immunity important to developing new therapeutics and vaccines.

Dr. Crowe received his MD degree from the University of North Carolina at Chapel Hill, where he also completed his pediatrics residency. Following his clinical training, Dr. Crowe received five years of post-doctoral training in the laboratory of Infectious Diseases at the NIH. He completed infectious diseases fellowship training in 1996 at Vanderbilt and has run an independent laboratory at Vanderbilt since that time. He is currently Professor of Pediatrics and of Pathology, Microbiology and Immunology, and the Ann Scott Carell Chair, Vanderbilt University Medical Center. The laboratory’s work has been published in over 300 publications in high-quality science journals including CellScience and Nature, and leading medical journals including the New England Journal of Medicine and JAMA. Dr. Crowe was elected to the National Academy of Medicine in 2014 and the National Academy of Inventors in 2017. He has been the recipient of investigator awards from the March of Dimes, American Society for Microbiology, Pediatric Infectious Diseases Society, and Society for Pediatric Research. He was awarded the Judson Infectious Daland Prize of the American Philosophical Society, the Oswald Avery Award of the IDSA, the E. Mead Johnson Award for Excellence in Pediatrics, the Outstanding Investigator Award of the American Federation for Medical Research, the Norman J. Siegel Award of the American Pediatric Society, the Samuel Rosenthal Prize for Excellence in Academic Pediatrics, the Stanley J. Korsmeyer Award of American Society for Clinical Investigation, the Distinguished Medical Alumnus Award from UNC School of Medicine, Chapel Hill, NC. He is an elected Fellow of AAM, AAAS, ASCI, and AAP, IDSA, APS, and others. His research team was selected as the Best Academic Research Team at the 11th Annual Vaccine Industry Excellence Awards. He was awarded the inaugural 2019 Merck Future Insight Prize, a 1M Euro prize shared with Pardis Sabeti. 

He is the Founder of IDBiologics, Inc., an early-stage biotech company developing human monoclonal antibodies for infectious diseases.

Daniel Chen, MD, PhD

CMO, IGM Bioscience

Daniel S. Chen, MD, PhD, is the Chief Medical Officer for IGM Biosciences, and former Vice President, Global Head of Cancer Immunotherapy Development at Genentech/Roche.  He received a BS degree in Biology from the Massachusetts Institute of Technology (1990), a PhD in Microbiology & Immunology (1996), and MD (1998) from the University of Southern California. His PhD work and publications focused on “Early Events in Coronavirus Infection.”

Daniel completed an Internal Medicine Residency and Medical Oncology Fellowship at Stanford University (2003). He went on to complete a Post-doctoral fellowship with Mark Davis in Immunology, where he was a Howard Hughes Medical Institute Associate. He also ran the metastatic melanoma clinic at the Stanford Cancer Center from 2003-2006. In that time, he studied human anti-cancer immune responses pre- and post-cancer vaccination and cytokine administration to determine why anti-tumor immune responses were not more clinically effective. He received a U19 grant to develop better immunologic tools to interrogate human immune responses and ultimately patented the MHC cellular microarray to detect and functionally characterize antigen-specific T cell states.

He continued as Adjunct Clinical Faculty at Stanford from 2006-2016, where he cared for melanoma patients. At Genentech from 2006-2018, Daniel focused on the clinical development of anti-angiogenic and immune-modulatory targeted therapies in both early and late development, as well as the diagnostic tools to aid their development. This included leading the clinical development for atezolizumab, a PD-L1 inhibitor, from the time the program was in research through IND, Phase I, Phase II, Phase III, to filing and approvals in multiple indications worldwide. At IGM, Daniel focuses on the development of novel engineered multivalent and multispecific therapeutics. He is a reviewer for Nature, Immunity, and Clinical Cancer Research, serves on the Board of Directors for SITC, co-chair of the CRI cancer Immunotherapy consortium, gave the keynote presentation at the AACR NCI EORTC Annual Meeting 2014 and presented at the US Congressional Briefing on Immuno Oncology in 2017. He has continued to publish with academic and industry collaborators in the field of cancer immunotherapy, including the often-referenced Chen and Mellman manuscripts, “Elements of cancer immunity and the cancer-immune set point” and “Oncology meets Immunology: The Cancer-Immunity Cycle.”

Imre Berger

Founding Director, Max Planck Bristol Centre; Chair in Biochemistry and Chemistry; University of Bristol UK

Imre Berger was trained as a biochemist and synthetic biologist at Leibniz University and Medical School (MHH) in Hannover (Germany), at MIT (Cambridge, USA), and at ETH Zurich (Switzerland). Imre’s team develops enabling methods for DNA delivery and genome engineering, engineers synthetic vaccines and nanosensors and researches the structure and mechanism of multiprotein complexes in human health and disease. After Group Leader posts at ETH (2005) and EMBL (2007), Berger joined Bristol as Full Professor of Biochemistry (2014) with a joint appointment in Chemistry (2019). He is Founding Director of the Max Planck Centre for Minimal Biology in Bristol, Director of the BBSRC/EPSRC research center for synthetic biology BrisSynBio and Co-director of the Bristol Biodesign Institute BBI.

Imre Berger holds international patents for DNA and protein technologies, co-founded three biotech companies, and received numerous distinctions, notably the Swiss Technology Award, the W.A. DeVigier Foundation Award, and a Wellcome Trust Senior Investigator Award for his innovative research. Since 2019, he is an Investigator of the European Research Council (ERC).

Prof. Berger has participated in leading roles in numerous European Commission (EC) projects, including the pan-European structural biology infrastructure INSTRUCT. He has been Coordinator of the EC FP7 HEALTH ComplexINC project enhancing production tools for complex biologics in academic and industrial R&D (2011-2016) and is partner in the EPSRC funded Innovative Future Vaccine Manufacturing Research Hub.

Sina Bavari, PhD

CSO, Edge BioInnovation Consulting and Management; former CSO, Scientific Director US Army Medical Research Institute of Infectious Diseases (USAMRIID)

Dr. Sina Bavari is the co-founder of Healion Bio. He is one of the lead (non-gov) scientific adviser to the World Health Organization on SARSCoV-2. He has spent over 30 years developing rapid response diagnostics, prophylaxis, therapeutics, and vaccines for some of the world’s deadliest infectious diseases. Prior to co-founding Healion Bio, Dr. Bavari founded Edge BioInnovation Consulting and Mgt. and was the Chief Scientific Officer and Scientific Director at USAMRIID (US Army Research Institute of Infectious Diseases), where he spent over twenty years leading the discovery and development of vaccines, therapeutics, and diagnostics or diseases such as SARS and MERS CoVs, Ebola, Marburg, Zika, Smallpox, Sudan, Nipah, alpha viruses, Anthrax and many others. He has worked extensively with the FDA to successfully develop clinically proven countermeasures for many so-called envelope viruses like SARS-CoV-2. Dr. Bavari has contributed to ~20 drug development candidates such as Remdesivir, 30 patents, and many IND filings. He has trained over 70 scientists and managed over 500 scientists and supporting staff. His work has resulted in over 350 publications in many of the leading scientific journals including Nature, Nature Medicine, Cell, Cell Hosts, New England Journal of Medicine and many others. He has degrees from USC, and the University of Nebraska where he received his PhD in Immunotoxicology and Pharmaceutical Science.

Therapeutics Pipeline for COVID-19

Get the latest updates, interviews and receive special offers

Pre-register Today!

Ralph Rogers, MD

Assistant Professor of Medicine, Clinician Educator, Infectious Diseases, Warren Alpert Medical School of Brown University

Ralph Rogers, MD is an infectious disease specialist at the Lifespan Cancer Institute. He earned his medical degree from The Warren Alpert Medical School of Brown University where he also completed his residency and fellowship in infectious diseases. Dr. Rogers is Assistant Professor of Medicine, Clinician Educator Division of Infectious Diseases Warren Alpert Medical School of Brown University. He is a member of the Infectious Diseases Society of America (IDSA), the American Society for Microbiology (ASM) and the American Society of Transplantation (AST).

John Sninsky, PhD

Consultant, Translational Sciences

John J. Sninsky, PhD is a translational medicine consultant with deep understanding of diagnostics and diagnostics paired with medicine intervention. John has served in senior management positions in small and large CLIA service laboratories and in vitro diagnostic kit companies including Cetus, Roche Molecular Systems, Celera, Quest and CareDx. He was a member of the pioneering Cetus team that developed and optimized PCR technology for research and diagnostic use; specifically, the virology team developed the HIV, HTLV, HPV, HCV and HBV PCR assays. John put in place a surveillance initiative for viral variants and presented at the first FDA PMA advisory meeting for HIV PCR approval.

Timothy J. O’Leary, MD, PhD

Adjunct Professor, Pathology, University of Maryland School of Medicine; Former Chief Research and Development Officer, Veterans Affairs

Timothy O’Leary, MD, is Adjunct Professor of Pathology at the University of Maryland and served as Chief Research and Development Officer (CRADO) of the Department of Veterans Affairs from 2013-2015. He holds a doctorate in physical chemistry from Stanford University and a medical degree from the University of Michigan.

He is certified in anatomic pathology by the American Board of Pathology and in molecular genetic pathology by the American Board of Pathology and the American Board of Medical Genetics. Prior to his VA service, O’Leary chaired the Department of Cellular Pathology and Genetics at the Armed Forces Institute of Pathology for more than 15 years. He joined VA in 2004 and served as Director of Biomedical Laboratory Research and Development, Director of Clinical Sciences Research and Development, and Deputy CRADO prior to his appointment as CRADO. O’Leary also served as a reserve member of the Public Health Service Commissioned Corps from 1979 to 2010, serving two tours on active duty. His research interests include genomics, proteomics, and ultrasensitive detection of biological toxins. He has served on numerous federal panels and advisory committees, including the Health and Human Services Clinical Laboratory Improvement Advisory Committee and the Food and Drug Administration Hematology and Devices Panel. O’Leary, the holder of four patents, has authored or co-authored more than 190 journal articles and numerous book chapters and technical reports. He is a past president of the Association for Molecular Pathology and served as editor-in-chief for the Journal of Molecular Diagnostics.